Novo Nordisk A/S

Viking Therapeutics is continuing to advance dual GLP-1/GIP receptor agonist VK2735 on two tracks for obesity, with a pair of Phase III trials of the weekly injectable formulation under way, while a P

The years of effort and expense Abivax has put into advancing obefazimod for ulcerative colitis (UC) have paid off now that the French firm has presented stellar results from a pair of Phase III trial

On the latest edition of the Scrip M&A Podcast , senior writer Joseph Haas talked about how political uncertainty and continued tight capital markets are affecting biopharmaceutical M&A a

At least officially, Bristol Myers Squibb and Pfizer’s are selling the anticlotting drug Eliquis (apixaban) directly to consumers to lower costs for patients, especially those who are uninsured, under